SCHEMBL954384

SCHEMBL954384

Cc1nc2ccc(Cl)nn2c1-c1nc(-c2ccccc2)c(C(=O)O)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 4/20 0.47
DBF4 Q9UBU7 4/20 0.47
SMN1; SMN2 Q16637 2/20 0.45
NTRK1 P04629 1/20 0.43
AKT1 P31749 1/20 0.41
AKT2 P31751 1/20 0.41
KDM4E B2RXH2 2/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 2/20 0.39
HTT P42858 1/20 0.39
PTGER1 P34995 3/20 0.39
RARA P10276 1/20 0.39
RARB P10826 1/20 0.39
RARG P13631 1/20 0.39
ALDH1A1 P00352 2/20 0.38
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38
NPSR1 Q6W5P4 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3780759 0.92 CDC7 (0.49) CDC7DBF4SMN1; SMN2NTRK1AKT1
Hydrochloric Acid SCHEMBL953590 0.91 CDC7 (0.48) CDC7DBF4SMN1; SMN2NTRK1AKT1
SCHEMBL956183 0.88 CDC7 (0.56) CDC7DBF4RARARARBRARG
SCHEMBL953255 0.78 CDC7 (0.49) CDC7DBF4SMN1; SMN2AKT1AKT2
SCHEMBL952456 0.77 CDC7 (0.51) CDC7DBF4SMN1; SMN2NTRK1KDM4E
SCHEMBL957444 0.74 CDC7 (0.54) CDC7DBF4SMN1; SMN2AKT1AKT2
SCHEMBL952459 0.72 TSHR (0.52) CDC7DBF4SMN1; SMN2KDM4EGAA
SCHEMBL974859 0.71 CDC7 (0.84) CDC7DBF4SMN1; SMN2KDM4ERAB9A
SCHEMBL953254 0.71 F2RL1 (0.45) CDC7DBF4SMN1; SMN2AKT1AKT2
SCHEMBL4911963 0.71 NTRK1 (0.56) SMN1; SMN2NTRK1AKT1AKT2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9139589-B2 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2015-09-22 US disclosed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 EP disclosed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 US disclosed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 CDC7 1063/4885DBF4 3779/4885SMN1; SMN2 3959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.